Center for Frontotemporal Dementia

We are currently recruiting for the following treatment trials:

Study Title:	A prospective, randomized, multi-center, double-blind, 26-week, placebo-controlled trial of memantine (10mg BID) for the frontal and temporal subtypes of frontotemporal dementia
Principal Investigator:	Murray Grossman, MD
Sponsor:	Forest Research Institute
Conditions Studied:	Frontotemporal Dementia, Semantic Dementia
Intervention:	10 mg of memantine or placebo taken twice-daily
Purpose:	The study is designed to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The study will also assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD) and lastly, whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia.
What is involved?	Frequency of Visits: Six visits and 2 phone calls over a period of 8 months, with visits more frequent at the beginning of the study. Testing: Neurological and physical examinations, cognitive testing and neuropsychiatric assessments, EKGs, blood and urine specimen collection, and vital signs.
Contact Info:	Lauren M. Massimo, MSN, CRNP Clinical Research Coordinator 3400 Spruce Street Department of Neurology 3 West Gates Building Philadelphia, PA 19104-4283 Office: 215-349-5725

Study Title:	A phase 2/3, randomized, double-blind, placebo- controlled study to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy
Principal Investigator:	Murray Grossman, MD
Sponsor:	Allon Therapeutics
Conditions Studied:	Progressive Supranuclear Palsy
Intervention:	30 mg of davunetide or placebo taken twice-daily, when both are administered intranasally for 52 weeks.
Purpose:	The primary objectives of this study is to determine whether davunetide is effective in managing signs and symptoms of Progressive Supranuclear Palsy. The study will also assess safety, as measured by reported Adverse Events, electrocardiograms, nasal examination and clinical laboratory measures.
What is involved?	Frequency of Visits: The study will include 8 visits and a final telephone contact. Optional lumbar punctures will be obtained from consenting subjects at screening to assess exploratory biomarkers Testing: Neurological and physical examinations, cognitive testing and neuropsychiatric assessments, EKG, MRI,blood and urine specimen collection,vital signs and optional Lumbar Puncture.
Contact Info:	Marianna Diloyan, RN, BSN, MPH Clinical Research Coordinator 3400 Spruce Street Department of Neurology 3 West Gates Building Philadelphia, PA 19104-4283 Office: 215-349-5725